BiotechTube

Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhaler

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Apr 15, 2022 → Aug 30, 2024

NCT ID
NCT05363202

About Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhaler

Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhaler is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Bronchial Asthma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05363202. Target conditions include Bronchial Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05363202Phase 3UNKNOWN

Competing Products

20 competing products in Bronchial Asthma

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaPhase 2
52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
77
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
77
Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
77
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
77
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
77
RoflumilastAstraZenecaPhase 3
77
RoflumilastAstraZenecaPhase 2/3
65
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
77
CiclesonideAstraZenecaPhase 3
77
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
52
MontelukastMerckApproved
85
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
85
inhaled corticosteroid therapyNovartisPhase 1/2
41
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
51
NivolumabBristol Myers SquibbPhase 2
51
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
49

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3
77
Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3
77
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3
77
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3
77
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% + PlaceboPhase 3
77